Fig. 5: Response of m6A-modified NCOA4 mRNA in PBMCs from radiation-exposed humans.
From: RNA N6-methyladenosine modification-based biomarkers for absorbed ionizing radiation dose estimation
a Schematic of clinical radiotherapy in cancer patients by partial body irradiation. Dose responding curves of the relative m6A levels of NCOA4 mRNA in PBMCs from partial body irradiated cancer patients by NCOA4 primer 3 (b) and primer 2 (c). Samples of control group (0 Gy) were collected within 1 week before the start of radiation (i.e., baseline, n = 30). The relative m6A levels of NCOA4 mRNA measured using NCOA4 primer 3 in PBMCs from humans of different occupations (healthy volunteers [HVs, n = 16] v.s. radiation workers [n = 6]) (d), age (younger HVs [<27 years, n = 8] v.s. older HVs [≥ 27 years, n = 8]) (e), and gender (male HVs [n = 9] v.s. female HVs [n = 7]) (f). All data are presented as means ± standard deviation (SD) and analyzed by two-sided Student’s t test. *P < 0.05, n.s., not significant. Source data are provided.
